Pfizer's Free Cash Flow (FCF) for the trailing twelve months (TTM) ended in September 2024 was $8,227 million. For the months ended in September 2024 (likely representing the third quarter), its total free cash flow was $6,063 million.
Free Cash Flow is a critical indicator of a company's financial health and its ability to generate cash after accounting for capital expenditures. It represents the cash a company has left over after paying for its operating expenses and capital assets, which can then be used for purposes such as paying dividends, repurchasing stock, or reducing debt.
Understanding Pfizer's Free Cash Flow
Free cash flow provides valuable insights into how efficiently a company generates cash from its operations. A robust FCF indicates that a company has sufficient funds to reinvest in its business, pursue growth opportunities, or return value to shareholders.
Here's a breakdown of Pfizer's recent free cash flow figures:
| Metric | Value (Million USD) | Period |
|---|---|---|
| Total Free Cash Flow | $6,063 | Months Ended September 2024 |
| Trailing Twelve Months (TTM) | $8,227 | Trailing Twelve Months Ended September 2024 |
These figures highlight Pfizer's cash-generating capabilities during these periods. Analyzing these trends over time, alongside other financial metrics, can offer a comprehensive view of the company's financial performance and operational efficiency.
For more detailed financial data and historical trends, you can refer to financial analysis platforms that track company performance.
